CL2015002802A1 - Composiciones y métodos para producir cetosis elevada y sostenida - Google Patents

Composiciones y métodos para producir cetosis elevada y sostenida

Info

Publication number
CL2015002802A1
CL2015002802A1 CL2015002802A CL2015002802A CL2015002802A1 CL 2015002802 A1 CL2015002802 A1 CL 2015002802A1 CL 2015002802 A CL2015002802 A CL 2015002802A CL 2015002802 A CL2015002802 A CL 2015002802A CL 2015002802 A1 CL2015002802 A1 CL 2015002802A1
Authority
CL
Chile
Prior art keywords
compositions
methods
produce high
ketosis
sustained ketosis
Prior art date
Application number
CL2015002802A
Other languages
English (en)
Inventor
Agostino Dominic Paul D
Patrick Arnold
Shannon Kesl
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51581503&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002802(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ South Florida filed Critical Univ South Florida
Publication of CL2015002802A1 publication Critical patent/CL2015002802A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSICION FARMACEUTICA QUE COMPRENDE AL MENOS UN ACIDO GRASO DE CADENA MEDIA Y AL MENOS UN COMPUESTO DE HIDROXIBUTIRATO; USO PARA ESTIMULAR LA CETOSIS, SUPRIMIR EL APETITO Y ESTIMULAR LA PERDIDA DE PESO EN UN MAMIFERO.
CL2015002802A 2013-03-19 2015-09-17 Composiciones y métodos para producir cetosis elevada y sostenida CL2015002802A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361803203P 2013-03-19 2013-03-19
US201461926664P 2014-01-13 2014-01-13

Publications (1)

Publication Number Publication Date
CL2015002802A1 true CL2015002802A1 (es) 2016-05-06

Family

ID=51581503

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015002802A CL2015002802A1 (es) 2013-03-19 2015-09-17 Composiciones y métodos para producir cetosis elevada y sostenida
CL2018000983A CL2018000983A1 (es) 2013-03-19 2018-04-17 Composiciones y métodos para producir cetosis elevada y sostenida (divisional de solicitud n°02802-2015).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2018000983A CL2018000983A1 (es) 2013-03-19 2018-04-17 Composiciones y métodos para producir cetosis elevada y sostenida (divisional de solicitud n°02802-2015).

Country Status (21)

Country Link
US (4) US9138420B2 (es)
EP (1) EP2976073B1 (es)
JP (2) JP6491189B2 (es)
KR (2) KR102499654B1 (es)
CN (1) CN105050594B (es)
AU (2) AU2014236004B2 (es)
BR (1) BR112015024186B1 (es)
CA (1) CA2902603C (es)
CL (2) CL2015002802A1 (es)
CR (1) CR20150579A (es)
HK (1) HK1216847A1 (es)
IL (2) IL241316B (es)
MX (2) MX371259B (es)
MY (1) MY180761A (es)
NZ (1) NZ711433A (es)
PE (1) PE20151949A1 (es)
PH (1) PH12015501966B1 (es)
RU (2) RU2018120938A (es)
SG (2) SG10201808690PA (es)
WO (1) WO2014153416A1 (es)
ZA (1) ZA201506387B (es)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280721A1 (en) 2003-06-03 2006-12-14 The Gov Of Usa Represented By Secretary Of Dpt Of Nutritional supplements and therapeutic compositions comprising (r)-3- hydroxybutyrate derivatives
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
JP6883384B2 (ja) 2012-11-05 2021-06-09 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 電離放射線による傷害から組織を防護するためのケトン体
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
AU2014240467B2 (en) 2013-03-14 2018-11-29 University Of Florida Research Foundation, Incorporated Regulation of cancer using natural compounds and/or diet
CN105246870A (zh) 2013-03-14 2016-01-13 伊希斯创新有限公司 (r)-3-羟基丁酸(r)-3-羟基丁酯的制备方法
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
RU2687750C2 (ru) 2014-04-02 2019-05-16 Юниверсити Оф Саутерн Калифорния Лечение аутоиммунной реакции и рассеянного склероза
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
CN107708688A (zh) * 2015-06-26 2018-02-16 佛罗里达大学研究基金会有限公司 使用天然化合物和/或饮食治疗炎症的方法
US10987340B2 (en) 2015-07-24 2021-04-27 Jesse Alexander Galinski Composition and method for rapidly inducing an endogenous ketosis
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10292952B2 (en) * 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US20170266147A1 (en) * 2016-03-18 2017-09-21 Csilla Ari D'Agostino Methods of increasing latency of anesthetic induction using ketone supplementation
WO2017165443A1 (en) * 2016-03-21 2017-09-28 Csilla Ari D'agostino Methods of improving motor function using ketone supplementation
US20190091189A1 (en) * 2016-03-21 2019-03-28 Csilla Ari D'Agostino Administration of exogenous ketone to lower blood glucose
US10376482B2 (en) 2016-04-03 2019-08-13 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US11173138B2 (en) * 2016-04-19 2021-11-16 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
CA3021639A1 (en) 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of berberine metabolites
US11337945B2 (en) 2016-06-01 2022-05-24 Keto Innovations, Llc C5 ketone compositions, and related methods, for therapeutic and performance supplementation
CA3026621A1 (en) 2016-06-07 2017-12-14 The J. David Gladstone Institutes Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same
US10588877B2 (en) 2016-07-21 2020-03-17 Savind, Inc. Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same
JP6935994B2 (ja) 2016-08-19 2021-09-15 株式会社明治 ケトン体生成促進用組成物
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
US11297873B2 (en) 2016-09-13 2022-04-12 Abbott Laboratories Ketogenic nutritional compositions
US10945975B2 (en) * 2016-10-24 2021-03-16 University Of South Florida Delaying latency to seizure by combinations of ketone supplements
US20180177753A1 (en) * 2016-12-23 2018-06-28 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for migraine symptom management
US9925164B1 (en) * 2017-01-12 2018-03-27 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for traumatic brain injury
EP4218550A1 (en) * 2017-03-08 2023-08-02 Abbott Diabetes Care Inc. Systems, devices, and methods for wellness and nutrition monitoring and management using analyte data
JP6951421B2 (ja) * 2017-03-28 2021-10-20 ロンザ・ソリューションズ・アー・ゲー 水溶性抗菌組成物
JP6968624B2 (ja) * 2017-04-06 2021-11-17 株式会社明治 ケトン食摂取量の管理方法
WO2018186481A1 (ja) * 2017-04-06 2018-10-11 株式会社明治 ケトン食の有効状態のモニタリング装置
EP3609484A4 (en) * 2017-04-12 2020-12-16 Cavaleri, Franco BUTYRATE AND BETA HYDROXYBUTYRATE COMPOSITIONS AND METHODS FOR THEIR USE
CN107083406B (zh) * 2017-05-27 2021-02-02 浙江华睿生物技术有限公司 (r)-3-羟基丁酸的生产方法
GB201710229D0 (en) 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
EP3654963A4 (en) 2017-07-21 2021-04-14 Buck Institute for Research on Aging BETA-HYDROXYBUTYRATE AND BUTANEDIOL S ENANTIOMERS AND THEIR METHODS OF USE
CN109394745A (zh) * 2017-08-17 2019-03-01 博瑞生物医药（苏州）股份有限公司 一种包含左旋肉碱和β-羟基丁酸化合物的组合物
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US20190119705A1 (en) * 2017-10-20 2019-04-25 KetoneAid Inc. Substantially non-racemic ketone ester of beta hydroxybutyrate and production process thereof
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
WO2019118624A1 (en) * 2017-12-12 2019-06-20 University Of South Florida Compositions and methods for weight loss maintenance
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
CN112105352A (zh) * 2018-01-05 2020-12-18 得克萨斯理工大学研究商业化办公室 与间歇性禁食相关的β-羟基-β-甲基丁酸(HMB)组合物和使用方法
RU2020128453A (ru) * 2018-02-01 2022-03-01 Веллстат Терапьютикс Корпорейшн Композиции и устройства для системной доставки уридина
US11241401B2 (en) * 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US20200061023A1 (en) * 2018-08-27 2020-02-27 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US10980772B2 (en) * 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11484542B2 (en) 2018-05-30 2022-11-01 Adam Slank Specialized tongue spray containing gymnemic acid and exogenous ketones
EP3801064A1 (en) * 2018-06-07 2021-04-14 Société des Produits Nestlé S.A. Methods and compositions for increasing ketone bodies in animals
CA3022995C (en) * 2018-06-12 2019-10-15 Ketofibe (9211-3133 Quebec Inc.) Novel ketogenic compounds, compositions, methods and use thereof
BR112020023132A2 (pt) * 2018-06-21 2021-02-09 Société des Produits Nestlé S.A. composições e métodos que usam um precursor de nicotinamida adenina dinucleotídeo (nad+) e pelo menos uma cetona ou um precursor de cetona
EP3843716A4 (en) * 2018-08-27 2022-06-01 Exerkine Corporation LYSOSOMAL DISEASE TREATMENT METHOD
US20200068939A1 (en) * 2018-09-04 2020-03-05 Jho Intellectual Property Holdings Llc Nutritional compositions to increase and sustain blood ketone levels
JP7499259B2 (ja) 2018-09-25 2024-06-13 ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー αケトグルタル酸カルシウムを製造するためのプロセス
US20210338613A1 (en) * 2018-10-05 2021-11-04 Dyve Biosciences, Inc. Formulations and methods for transdermal administration of ketones
EP3873442A4 (en) * 2018-10-29 2022-08-10 Keto Patent Group, Inc. MANUAL ADMINISTRATION OF BUTYRATE, BETA-HYDROXYBUTYRATE, CANNABIDIOL AND RELATED COMPOUNDS
CN109480284A (zh) * 2018-12-05 2019-03-19 上海欣海生物科技有限公司 一种生酮食品及其制备方法
BR112021007958A2 (pt) * 2018-12-18 2021-07-27 Société des Produits Nestlé S.A. triglicerídeos mistos
CN109734575A (zh) * 2019-01-04 2019-05-10 上海欣海国际贸易有限公司 一种制备3-羟基丁酸氨基酸盐复合物的方法
CA3129541A1 (en) * 2019-02-11 2020-08-20 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
CN113660930A (zh) * 2019-02-11 2021-11-16 阿克塞斯全球科学有限责任公司 β-羟基丁酸盐混合盐-酸组合物和使用方法
JP7448554B2 (ja) * 2019-02-11 2024-03-12 アクセス・グローバル・サイエンシーズ・エルエルシー Ｓ－ベータ－ヒドロキシブチレート化合物およびｓ－エナンチオマー富化組成物
JP7281927B2 (ja) * 2019-03-14 2023-05-26 大阪瓦斯株式会社 心拍数低減剤
CA3129569A1 (en) * 2019-03-14 2020-09-17 Thomas Weimbs Methods and compositions for supporting renal health
CN113543780A (zh) 2019-03-22 2021-10-22 雀巢产品有限公司 使用在餐前施用的中链甘油三酯来降低来自餐食的餐后葡萄糖的方法
WO2020193291A1 (en) * 2019-03-22 2020-10-01 Société des Produits Nestlé S.A. Methods using administration of medium chain triglycerides (mct) prior to a meal to increase ketone production from the mcts
WO2020249198A1 (de) * 2019-06-12 2020-12-17 Ioi Oleo Gmbh Verfahren zur herstellung von polyolbasierten estern von acylverkappten 3-hydroxycarbonsäuren
CN113993833B (zh) * 2019-06-12 2024-05-10 凯托利皮克斯治疗有限责任公司 酰基封端的3-羟基羧酸及其盐和酯的生产方法
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11915605B2 (en) 2019-10-17 2024-02-27 Nicolas Tzenios Ketogenic diet recommendation to a user based on a blood low-density lipoprotein (LDL) level and a blood C-reactive protein level and/or a blood erythrocyte sedimentation rate (ESR) thereof
WO2021150928A1 (en) * 2020-01-23 2021-07-29 University Of South Florida Prevention and treatment of effects of aging and age-associated disorders with ketone supplementation
WO2021178547A1 (en) 2020-03-05 2021-09-10 Devon Price COMPOSITION OF (D)-β-HYDROXYBUTYRIC ACID, (D)-β-HYDROXYVALERIC ACID, AND (D)-1,3 BUTANEDIOL AS A NUTRITIONAL SUPPLEMENT AND THERAPEUTIC AGENT
JP2023529504A (ja) * 2020-06-14 2023-07-10 エル－ニュートラ・インコーポレイテッド ファスティング状態を維持及び延長する断続的なファスティングバー／ドリンク
WO2022006500A1 (en) * 2020-07-02 2022-01-06 Ponce De Leon Health Designated Activity Company Compositions and methods for treating crp-mediated diseases
US20220062216A1 (en) * 2020-08-26 2022-03-03 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
CN112137115A (zh) * 2020-09-25 2020-12-29 深圳市捷利康生物科技有限公司 具有增强免疫力功效的生酮营养粉及其制备方法
WO2022140279A1 (en) * 2020-12-22 2022-06-30 Buck Institute For Research On Aging Synergistic modulators of alpha-dicarbonyl detoxification and their use for inducing weight loss and the treatment of diabetic pathologies
CN115968364A (zh) * 2021-04-16 2023-04-14 南京纽邦生物科技有限公司 低铅和低砷的β-羟基丁酸盐及其生产方法
US20240197659A1 (en) * 2021-04-26 2024-06-20 University Of South Florida Methods for treating symptoms of kabuki syndrome
RU2769242C1 (ru) * 2021-06-16 2022-03-29 Александр Владимирович Чемоданов Кетогенная композиция
EP4363599A1 (en) 2021-06-28 2024-05-08 PHB Industrial S.A. Methods to produce therapeutic formulations comprising hydroxybutirate and hydroxyvalerate, therapeutic formulations and uses thereof
WO2023112818A1 (ja) * 2021-12-14 2023-06-22 サントリーホールディングス株式会社 炭酸飲料及び炭酸飲料の炭酸感を増強する方法
WO2023112817A1 (ja) * 2021-12-14 2023-06-22 サントリーホールディングス株式会社 ３ヒドロキシ酪酸及び低級脂肪族アルコールを含有する飲料及び呈味改善方法
CN114306308A (zh) * 2021-12-24 2022-04-12 苏州麦轮生物科技有限公司 一种含有酮酯的营养补充剂及其应用
WO2023139357A1 (en) * 2022-01-18 2023-07-27 Today Inc. Molecules, nutritional formulations, and methods of providing nutritional support
JP7223193B1 (ja) 2022-05-26 2023-02-15 大阪瓦斯株式会社 内臓脂肪低減剤およびその用途
CN115192603B (zh) * 2022-07-06 2023-04-21 西北农林科技大学 锂盐在制备防治奶牛酮病制剂中的应用
CN115251375A (zh) * 2022-07-11 2022-11-01 珠海麦得发生物科技股份有限公司 一种(r)-3-羟基丁酸生酮产品及其制备方法
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8803141L (sv) * 1988-09-07 1990-03-08 Kabivitrum Ab Naeringsmedel foer maenniskor och djur
US5654266A (en) * 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US20090253781A1 (en) 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
ZA982253B (en) * 1997-03-17 1999-09-17 British Tech Group Therapeutic compositions.
JPH1160434A (ja) 1997-08-12 1999-03-02 Kanebo Ltd 皮膚老化防止化粧料
JP2002521330A (ja) * 1998-07-22 2002-07-16 メタボリックス，インコーポレイテッド ３−ヒドロキシアルカン酸オリゴマーの栄養的および治療的使用
AU767238B2 (en) 1998-09-15 2003-11-06 Btg International Limited Therapeutic compositions (II)
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
JP2003531857A (ja) 2000-05-01 2003-10-28 アクセラ・インコーポレーテッド アルツハイマー病およびニューロンの代謝の減少によって引き起こされる他の病気を治療および予防するための中鎖トリグリセリドの使用
US6613356B1 (en) 2000-10-10 2003-09-02 Victor Vlahakos Weight loss medication and method
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US8158184B2 (en) * 2004-03-08 2012-04-17 Bunge Oils, Inc. Structured lipid containing compositions and methods with health and nutrition promoting characteristics
GB0410266D0 (en) * 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
GB0420856D0 (en) 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
US20070135376A1 (en) * 2005-06-20 2007-06-14 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
DK2500017T3 (da) * 2006-04-03 2017-11-06 Accera Inc Anvendelse af ketogene forbindelser til behandling af aldersrelateret hukommelsessvækkelse
US7807718B2 (en) 2006-06-30 2010-10-05 Sami A. Hashim Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
EP2146711A4 (en) * 2007-04-12 2011-10-26 Univ Minnesota PROTECTIVE COMPOSITIONS AGAINST ISCHEMIA / REPERFUSION AND METHODS OF USE
DK2240017T3 (da) * 2008-01-04 2019-06-17 Univ Oxford Innovation Ltd Ketonlegemer og ketonlegemsestere som blodlipid-sænkende midler
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
GB201206192D0 (en) 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output

Also Published As

Publication number Publication date
JP6491189B2 (ja) 2019-03-27
RU2018120938A (ru) 2018-11-06
HK1216847A1 (zh) 2016-12-09
IL259502A (en) 2018-07-31
MX2019010248A (es) 2019-10-09
BR112015024186A2 (pt) 2017-07-18
CN105050594B (zh) 2019-11-12
IL241316A0 (en) 2015-11-30
US9675577B2 (en) 2017-06-13
PE20151949A1 (es) 2016-01-05
CL2018000983A1 (es) 2018-10-12
CA2902603A1 (en) 2014-09-25
US10646462B2 (en) 2020-05-12
IL241316B (en) 2018-08-30
RU2018120938A3 (es) 2019-04-04
EP2976073A1 (en) 2016-01-27
JP2019031578A (ja) 2019-02-28
US20200268701A1 (en) 2020-08-27
AU2014236004A1 (en) 2015-09-10
US20170266148A1 (en) 2017-09-21
CR20150579A (es) 2016-01-04
CN105050594A (zh) 2015-11-11
RU2015136190A (ru) 2017-03-10
KR20220011785A (ko) 2022-01-28
WO2014153416A1 (en) 2014-09-25
SG11201506780RA (en) 2015-10-29
BR112015024186B1 (pt) 2023-05-09
US20160067207A1 (en) 2016-03-10
PH12015501966A1 (en) 2016-01-11
MY180761A (en) 2020-12-08
SG10201808690PA (en) 2018-11-29
US20140350105A1 (en) 2014-11-27
KR102499654B1 (ko) 2023-02-13
CA2902603C (en) 2021-03-02
KR20150130312A (ko) 2015-11-23
EP2976073A4 (en) 2017-02-22
US9138420B2 (en) 2015-09-22
JP2016514725A (ja) 2016-05-23
IL259502B (en) 2019-09-26
NZ711433A (en) 2017-03-31
MX2015013312A (es) 2016-06-07
EP2976073B1 (en) 2019-08-28
MX371259B (es) 2020-01-23
RU2659386C2 (ru) 2018-06-29
ZA201506387B (en) 2017-08-30
AU2019200511A1 (en) 2019-02-14
AU2014236004B2 (en) 2018-10-25
PH12015501966B1 (en) 2016-01-11

Similar Documents

Publication Publication Date Title
CL2015002802A1 (es) Composiciones y métodos para producir cetosis elevada y sostenida
AR096897A1 (es) Transferencia de peso en un implemento con control de realimentación
CL2016000508A1 (es) Compuestos derivados de (2-metil-3-fenilfenil)metoxi sustituidos, inhibidores de la interacción pd-1/proteína pd-l1/proteína; composición farmacéutica que los comprende; y su uso para tratar una enfermedad infecciosa o cáncer.
CL2012002859A1 (es) Metodo para reducir el peso de un sujeto que comprende el uso de un modulador antioxidante de la inflamacion.
CL2016000017A1 (es) Carboxamidas de anillo de 4 miembros empleadas como nematicidas
EP2997246A4 (en) Piston having combustion bowl shaped to balance combustion efficiency and emission properties
CR20130680A (es) Métodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales i
CO6831975A2 (es) Inmunoconjugados, composiciones para prepararlos, métodos para prepararlos y uso
ES2838803T3 (es) Método para reducir la producción total de gas y/o la producción de metano en un animal rumiante
CO2017002253A2 (es) Compuesto dirigido a il-23a y tnf-alfa
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
CR20160400A (es) Derivados de nucleosido sustituidos con 4´-difluorometilo como inhibidores de la replicación de arn de la influenza
DOP2014000098A (es) 2-tiopirimidinonas
UY34406A (es) Compuestos y métodos para mejorar la respuesta inmune innata
AR087093A1 (es) Composicion que mejora la palatabilidad que comprende aminoacidos libre para usar en alimentos para mascotas
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
UY34751A (es) ?composición de pienso para reducir la metanogénesis en rumiantes?
AR092566A1 (es) Composiciones grasas para mantener una palatabilidad de alimentos para animales domesticos en el tiempo
NI201600006A (es) Pirazolo-piridinaminas sustituidas
CL2015003584A1 (es) Compuestos nuevos para el tratamiento del cáncer.
CR20160066A (es) Compuestos y métodos para mejorar el rendimiento de una planta
CL2012000508A1 (es) Composicion para la aplicacion en cultivos agricolas al aire libre o invernaderos que comprende zeolita, y aditivos; uso de la composicion para aumentar el rendimiento de los cultivos agricolas.
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
CL2015001289A1 (es) Nuevos derivados de 1,4-ditiina sustituida y su uso como fungicidas
CL2014001834A1 (es) Uso de semilla de palta con el fin de obtener mediante presion mecanica aceite de palta enriquecido en alquil polioles, donde dichas semillas representan el 10 al 50% en peso en relacion con el peso total de la palta utilizada; metodo para obtener aceite de palta; y aceite de palta enriquecido; uso de aceite de palta; e insaponificable de palta.